Organoid Science and MitoImmune Therapeutics (hereinafter referred to as MitoImmune) signed a memorandum of understanding (MOU) for joint research and development. This business agreement is a strategic partnership that focuses not only on common goals but also on promoting the advancement of the pipelines and services that both companies possess.
Mitoimmune is Korea’s first innovative new drug developer targeting mitochondria and has the ‘MIT-Platform’, which fundamentally blocks the release of inflammatory factors by inhibiting ferroptosis, an iron-dependent cell death that has recently attracted attention. . MIT-001, the leading pipeline using this, is undergoing global phase 2 clinical trials as a treatment for oral mucositis. We are also working on research and development of treatments for degenerative brain diseases, including Alzheimer’s, and are expanding our research area to incurable diseases for which there are no treatments, such as fibrosis and immune diseases.
Organoid Science is also the first developer in Korea to technologyize the unique advantages of organoids. The organoid-based material evaluation platform ‘ODISEI’, which has already been proven in the industry, has a high degree of human simulation and can accurately evaluate the efficacy of new drugs in development for most diseases, including anticancer drugs, brain diseases, and infectious diseases. ‘ATORM’, an organoid-based regenerative treatment that overcomes the limitations of existing regenerative treatments by having an immediate regenerative function without going through a differentiation process, is scheduled to enter clinical trials within the year.
While both companies are leading innovation based on different core technologies, their research areas have many things in common, including anticancer drugs, central nervous diseases, rare diseases, and treatments for incurable diseases. As such, this agreement goes beyond the establishment of a simple cooperative relationship to develop new drug pipelines and services for both companies. It is becoming more important as a purpose of advancement.
Sunha Kim, CEO of MitoImmune, said, “If we have been focusing on researching our own platform technology and strengthening the clinical pipeline, now it is time to use the organoid platform to further rapidly expand and advance MitoImmune’s development area.” “We expect that Organoid Science’s technology will play a significant role in the successful clinical development of regenerative treatments.”
Jongman Yoo, CEO of Organoid Science, said, “Through this agreement, we are pleased that the organoid-based platform will have the opportunity to prove the outstanding efficacy and technological excellence of the substances that MitoImmune is developing.” He added, “The organoids that the company is currently preparing are “We expect it to be a great foundation for differentiation and quality advancement in the basic service business.”
Source: Pangyo Techno Valley Official Newsroom
→ Go to ‘Asian Innovation Hub Pangyo Techno Valley 2022’ news